Welcome to LookChem.com Sign In|Join Free
  • or

55268-74-1

Post Buying Request

55268-74-1 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Praziquantel 55268-74-1
Cas No: 55268-74-1
USD $ 75.0-75.0 / Kilogram 1 Kilogram 5 Metric Ton/Month EnBridge PharmTech Co., Ltd. Contact Supplier
Praziquantel
Cas No: 55268-74-1
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-10 Metric Ton/Month Dayang Chem (Hangzhou) Co.,Ltd. Contact Supplier
High quality praziquantel as wormer
Cas No: 55268-74-1
USD $ 135.0-135.0 / Kilogram 1 Kilogram 600 Kilogram/Day Xi'an Harmonious Natural Bio-Technology Co., Ltd. Contact Supplier
Factory Directly Supply API 99% praziquantel powder CAS NO.55268-74-1
Cas No: 55268-74-1
USD $ 30.0-50.0 / Kilogram 1 Kilogram 500 Kilogram/Month Mike(Wuhan) Biotechnology Co.,Ltd Contact Supplier
Praziquantel
Cas No: 55268-74-1
No Data 25 Kilogram Metric Ton/Day HANGZHOU CLAKE BIOTECH CO.,LTD Contact Supplier
Praziquantel CAS:55268-74-1
Cas No: 55268-74-1
USD $ 82.0-105.0 / Kilogram 1 Kilogram 99999 Kilogram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
Praziquantel
Cas No: 55268-74-1
No Data 1 Gram 1000 Gram/Month Boc Sciences Contact Supplier
Biggest manufacturer of Praziquantel
Cas No: 55268-74-1
No Data 1 Kilogram 10 Metric Ton/Month Zhengzhou Yuanli Biological Technology Co., Ltd. Contact Supplier
Praziquantel -- CHemwill
Cas No: 55268-74-1
USD $ 1.0-1.0 / Metric Ton 1 Metric Ton 5 Metric Ton/Day Chemwill Asia Co., Ltd. Contact Supplier
Praziquantel
Cas No: 55268-74-1
USD $ 105.0-110.0 / Kilogram 1 Kilogram 20 Metric Ton/Year Sinoway Industrial Co., Ltd. Contact Supplier

55268-74-1 Usage

Brand name

Biltricide (Bayer).

Storage Characteristics

ventilation, low-temperature, and drying.

Chemical Synthesis

Praziquantel, 2-(cyclcohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino [2,1a]isoquinolin-4-one (38.1.15), is a derivative of pyrazinoquinoline that is made in two ways. According to one of them, 1-aminomethyl-1,2,3,4-tetrahydroisoquinoline is alkylated with chloroacetic acid, and then the resulting amine is acylated with cyclohexanecarbonyl chloride to make 1-(N-carboxymethyl-N-cyclohexylcarbonylaminomethyl)-1,2,3,4-tetra-hydroisoquinoline (38.1.14), which is heated at 150°C to give the desired praziquantel. Another way of synthesizing this drug begins with isoquinoline, which is reacted with a mixture of cyclohexanecarbonyl chloride / potassium cyanide to make a dihydro derivative of isoquinoline (38.1.16). This is reduced by hydrogen over Raney nickel to give the reduction–reamidation product—the amide 1-(N-cyclohexylcarbonylaminomethyl)- 1,2,3,4-tetrahydroisoquinoline (38.1.17). Acylating this with chloracetic acid chloride gives a chlroacetyl derivative (38.1.18), which when heated in the presence of diethylamine results in an intramolecular alkylation, giving the desired product—prazi quantel.

Metabolism

Praziquantel is rapidly absorbed and undergoes hepatic first-pass metabolism. The metabolites are either less active or inactive and consist of hydroxylated compounds. In the serum, the major metabolite appears to be the monohydroxylated 4-hydroxycyclohexylcarboxylate, whereas in the urine, 50 to 60% of the initial PZQ exists as dihydroxylated products.图 These hydroxylation reactions are catalyzed by CYP2B6 and CYP3A4. The metabolites would be expected to exist in the conjugated form in the urine.

Mechanism of action

Praziquantel is readily absorbed (80% in 24 hours) after oral administration, with serum concentrations being maximal in 1 to 3 hours; the drug has a half-life of 0.8 to 1.5 hours. Its bioavailability is reduced by phenytoin or carbamazepine and increased by cimetidine. Dexamethasone decreases plasma praziquantel levels by 50%. Praziquantel is excreted by the kidneys.

Interactions

Phenytoin, carbamazepine, and dexamethasone have been reported to decrease the plasma concentrations of praziquantel by 10% to 50% 【17, 18】. The clinical relevance of these interactions for the treatment of parasitic infections needs further investigation.

Indications

Infections caused by Schistosoma species pathogenic to man (Schistosoma haematobium, S. mansoni, S. japonicum and S. mekongi). The drug is most cost-effective in mixed infections. It is also effective for infections with flukes (Paragonimus westermani and Clonorchis sinensis) and in cestodes (Hymenolepis nana, Diphyllobotrium latum, Taenia saginata, T. solium) including the larval stage of Taenia solium (cysticercosis). Praziquantel has some effect against fascioliasis, but triclabendazole, a new anthelminthic drug still under clinical evaluation is more effective.

Pharmacokinetics

Oral absorption: >80% Cmax 50 mg/kg oral: 1 mg/L after 1–2 h Plasma half-life: parent drug: 1–1.5 h metabolites: 4–6h Plasma protein binding: 80% Praziquantel is rapidly absorbed when given orally, but it undergoes extensive first-pass biotransformation and the concentration of unchanged drug in plasma is low. The major metabolite, a 4-hydroxy derivative, retains little to no antiparasitic activity. About 80% of the oral dose, as parent drug and its metabolites, is excreted in the urine by the fourth day post-treatment, 90% of this in 24 h. A higher peak plasma concentration is achieved in infected people, but other pharmacokinetic values are unchanged.

Indications

The neuromuscular effects of praziquantel (Biltricide) appear to increase parasite motility leading to spastic paralysis. The drug increases calcium permeability through parasite-specific ion channels, so that the tegmental and muscle cells of the parasite accumulate calcium.This action is followed by vacuolization and the exposure of hitherto masked tegmental antigens, lipidanchored protein, and actin. Insertion of the drug into the fluke’s lipid bilayer causes conformational changes, rendering the fluke susceptible to antibody- and complement-mediated assault.

Description

Praziquantel (PZQ) is an isoquinoline derivative with most of the biological activity found in the levo enantiomer. The compound has no activity against nematodes, but it is highly effective against cestodes and trematodes.

Acquired resistance

There is evidence that resistance to praziquantel is emerging in schistosomes, although there is debate as to whether treatment failures are due to resistance or innate tolerance.

Toxicity grading

Poisoning

Pharmacology and mechanism of action

Praziquantel is a pyrazinoquinoline compound originally developed for the treatment of schistosomiasis but has been found to have a wide spectrum of anthelminthic activity. Praziquantel is a racemate but the R (+) enantiomer is solely responsible for its antiparasitic activity. It is active against trematodes (all Schistosoma species pathogenic to man, Paragonimus westermani, and Clonorchis sinensis) and cestodes (Taenia saginata, Taenia solium, Hymenolepis nana and Diphyllobothrium latum) 【1】. The mechanism of action of praziquantel is not clearly known. Schistosomes take up the drug rapidly. Drug uptake is immediately followed by increased muscular activity that proceeds to tetanic contraction and vacuolization of the parasite tegument 【2】. The muscular effects of the drug are presumed to be responsible for the shift of the parasites from the mesenteric veins to the liver in vivo. However, hepatic shift has been demonstrated with most known schistosomicides and may not provide any specific information of the drug’s mechanism of action. Recent experimental findings have suggested that the antischistosomal effects of the drug are related to its effect on the tegument rather than on the musculature 【3】. Another pharmacological effect of the drug includes an increase of membrane permeability to cations, particularly calcium 【4】. However, the role of this effect to the anthelminthic property of the drug is unknown.

Clinical Use

Praziquantel is an extremely active broad-spectrum anthelmintic that is well tolerated. It is the most effective of the drugs used in the treatment of schistosomiasis, possessing activity against male and female adults and immature stages. Unlike other agents, it is active against all three major species (S. haematobium, S. mansoni, and S. japonicum). In addition, it has activity against other flukes, such as C. sinensis, Paragonimus westermani, O. viverrini, and the tapeworms (D. latum, H. nana, T. saginata, and T. solium). It is not as effective against F. hepatica. It is used effectively in the treatment of clonorchiasis and paragonimiasis and is an effective alternative agent to niclosamide in the treatment of tapeworm infestations.

Safety Profile

Poison by intraperitoneal route.Moderately toxic by ingestion and other routes. Humanmutation data reported. When heated to decomposition itemits toxic fumes of NOx.

Veterinary Drugs and Treatments

Praziquantel is indicated for (approved labeling) for the treatment of Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosis in dogs, and Dipylidium caninum and Taenia taeniaeformis in cats. Fasting is not required nor recommended before dosing. A single dose is usually effective, but measures should be taken to prevent reinfection, particularly against D. caninum. Praziquantel can also be used for treating Alaria spp. in dogs and cats and Spirometra mansonoides infections in cats. Praziquantel has been used in birds and other animals, but it is usually not economically feasible to use in large animals. In humans, praziquantel is used for schistosomiasis, other trematodes (lung, liver, intestinal flukes) and tapeworms. It is not routinely effective in treating F. hepatica infections in humans. Combination products can give a wide spectrum of internal parasite control in a variety of species.

Pharmaceutical Applications

A synthetic pyrazinoquinoline formulated for oral administration. It is stable in the dry state, but hygroscopic.

The treatment of schistosomiasis

Schistosomiasis is parasitic disease with both human and animal being prone to get infected. Schistosome has a relative complicated life history. Adult parasites live in the mesenteric vein and portal vein blood of people, cattle, pigs and some other mammals, and therefore humans and these animals are called as the adult host or definitive host. Praziquantel is a kind of common drugs for treatment of schistosomiasis with an extremely small animal toxicity. After its oral administration, it is rapidly absorbed in the digestive tract. The time of the plasma concentration for reaching peaks: 5 minutes for mice, l5~30 minutes for rat, 30 to 120 minutes for dogs, and 2 h for sheep. After its absorption this drug is widely distributed in all tissues and organs; it is even able to penetrate through the blood-brain barrier of rats and can also enter into the bile of dogs. It can induce of influx of the Ca 2+ located outside of the schistosome parasite muscle cell membrane, and thus causing muscle contractures and loss of ability of sucking parasite location. At the same time, it also causes deficiency in sugar metabolism and energy metabolism, disrupting the "With immunization" state and then working together with the host immune system for finally eliminating the parasites. Therefore, it has good killing efficacy in treating China branch schistosomiasis, tapeworm, lung fluke, cysticercosis and also immature parasites (cercariae and miracidia). The common side effects of praziquantel are as follows: 1. during the first 1 hour of medication of the first time: dizziness, headache, nausea, abdominal pain, diarrhea, fatigue, aching limbs can occur, usually at a lesser extent and short duration, and does not affect the treatment without specific treatment. 2. in a few cases, there may be symptoms such as heart palpitations, chest tightness, and T wave change and primary contraction in ECG; supraventricular tachycardia and atrial fibrillation can sometimes also happen. 3. in a few cases there may be a transient increase in transaminases and toxic hepatitis. 4. it sometimes can induce mental disorders and gastrointestinal bleeding. 5. hernia, allergic reactions (rash, asthma), etc. are also seen.

Uses

It is a kind of broad-spectrum anti-parasitic disease drug. It can be used for the treatment and prevention of schistosomiasis, cysticercosis, paragonimiasis, hydatid disease, fasciolopsiasis, hydatid disease, and worm infection. It can also be used as anthelmintic and is effective in treating animal gastrointestinal nematodes. It can be mixed in the feed for application. The product is a kind of anthelmintic drug effective in treating Schistosoma japonicum, Schistosoma mansoni and Schistosoma haematobium, Clonorchis sinensis, Paragonimus westermani, fasciolopsis buski, tapeworms and cysticercosis. It has a especially strong killing effect on tapeworm and is currently of highest efficiency among anti-schistosomiasis drug. It is a kind of anthelmintics drug mainly used for treating schistosomiasis. It can also used for treating Fahrenheit schistosomiasis, taeniasis, paragonimiasis, and cysticercosis

Production method

There are a variety of synthetic routes (isoquinoline route, piperazine route, and phenethylamine route). Isoquinoline has advantages such as wide sources of initial raw material and low cost. Isoquinoline can be converted to 1-benzoyl-2-cyano-1,2-dihydro-isoquinoline through Reissetr reaction. It is further converted to 1-benzoyl-aminomethyl-1, 2, 3, 4-tetrahydroisoquinoline through pressurized hydrogenation. Then followed by cyclization with chloroacetyl chloride to give 2-benzoyl-1,3, 4,6,7,11b-hexahydro-2H-pyrazino[2,1-b]isoquinolin-4-ketone. Finally, apply phosphoric acid hydrolysis and perform condensation reaction with cyclohexanecarboxylic acid chloride to obtain the final product. There are a variety of synthetic routes for industrial production including isoquinoline route, piperazine route, and phenethylamine route, among which the isoquinoline route is the best. In this route, first perform adduct reaction between isoquinoline and benzoyl chloride as well as potassium cyanide, further go through catalytic hydrogenation and rearrangement to generate 1-benzoyl-methyl-amino-1,2,3,4-tetrahydroisoquinoline, and then sequentially go through chlorine acetylation, cyclization, hydrolysis under increased pressure, and cyclohexanone acylation to generate the final product. Take phenethylamine as the raw material, after acylation through chloroacetyl chloride, further introduce the amino group after adding terephthalamide potassium for amination reaction, then have cyclization reaction in the action of phosphorus oxychloride to give 3,4-dihydroisoquinoline derivative; further go through hydrogenation and hydrolysis to obtain 1-aminomethyl-tetrahydroquinoline; successively use cyclohexane carboxylic acid chloride and chloroacetyl chloride for acylation and finally go through dehydrochlorination and cyclization to obtain praziquantel. You can alternatively use isoquinoline as raw material; it first go through Reissert reaction to introduce a cyano group in l position and have nitrogen benzoylated, followed by hydrogenation while benzoyl group is transferred to the amino group of the side chain, further introduce a chlorine acetyl group to the amino group on the ring, then successively go through cyclization, hydrolysis, cyclohexanone formylation to obtain praziquantel. The above information is edited by the chemicalbook of Dai Xiongfeng.

Preparations

Biltricide? (Bayer). Tablets 600 mg. Cysticide? (E.Merck). Tablets 500 mg. Cesol? (E.Merck). Tablets 150 mg.

Uses

anthelmintic; EMBAY-8440

Category

Toxic substances

Originator

Cesol ,Merck ,W. Germany ,1980

Manufacturing Process

15 g of a nickel-aluminum alloy (1:1) is introduced in incremental portions and under agitation into 200 ml of 20% sodium hydroxide solution within 5 minutes; the mixture is maintained at 80°C for 45 minutes, then allowed to settle, decanted off, washed with water, and 1,000 ml of 1% (-)-tartaric acid solution is added thereto, adjusted to pH 5 with 1 N sodium hydroxide solution. The mixture is heated under agitation for 90 minutes to 80°C, decanted, and washed with water and methanol. The thus-obtained (-)tartaric acid-Raney nickel catalyst is added to a solution of 2cyclohexylcarbonyl-4-oxo-2,3,6,7-tetrahydro-4H-pyrazino[2,1-a]isoquinoline. The reaction mixture is hydrogenated under normal pressure and at room temperature. After the catalyst has been filtered off and the solvent evaporated, 2-cyclohexylcarbonyl-4-oxo-1,2,3,6,7,11b-hexahydro-4Hpyrazino[2,1-a]isoquinoline, melting point 136°C to 138°C, is produced.

Therapeutic Function

Anthelmintic

Uses

Anthelmintic, effective against flatworms.

Chemical Properties

White Solid

Clinical Use

2-(Cyclohexylcarbonyl)-1,2,3,6,7, 11b-hexahydro-4Hpyrazino[2,1-a]isoquinolin-4-one (Biltricide) is a broadspectrumagent that is effective against various trematodes (flukes). It has become the agent of choice for the treatmentof infections caused by schistosomes (blood flukes).The drug also provides effective treatment for fasciolopsiasis(intestinal fluke), clonorchiasis (Chinese liver fluke),fascioliasis (sheep liver fluke), opisthorchosis (liver fluke),and paragonimiasis (lung fluke). Praziquantel increases cellmembrane permeability of susceptible worms, resulting inthe loss of extracellular calcium. Massive contractions andultimate paralysis of the fluke musculature occurs, followedby phagocytosis of the parasite.Following oral administration, about 80% of the doseis absorbed. Maximal plasma concentrations are achievedin 1 to 3 hours. The drug is rapidly metabolized in theliver in the first-pass. It is likely that some of the metabolitesare also active. Praziquantel occurs as a white crystallinesolid that is insoluble in water. It is available as600-mg film-coated tablets. The drug is generally welltolerated.

Chemical Properties

It is white or almost white crystalline powder; it is odorless with a slightly bitter taste. It also has hygroscopic effect. Solubility (g/100m1): 9.7 in ethanol, 56.7 in chloroform, and 0.04 in water. It is easily soluble in dimethyl sulfoxide (DMSO), but insoluble in ether. It has a melting point of 136~141 ℃. Acute toxicity LD50 in mice and rats (mg/kg): 2000~3000 oral administration,> 3,000 subcutaneously injection.

Acute toxicity

Oral rat LD50; 2840 mg/kg; Oral-Mouse LD50: 2454 mg/kg.

Extinguishing agent

Dry powder, foam, sand, carbon dioxide, water spray.

Side effects

Very few side effects have been reported. In the treatment of cerebral cysticercosis the death of cysts in the brain may cause local inflammation and edema, but this usually subsides quickly. Ocular cysticercosis should not be treated with this drug, because parasite destruction in the eye can lead to irreparable lesions. Adverse events seen in the treatment of schistosomiasis, including abdominal pain, nausea, anorexia, diarrhea and mild neurological effects, are almost certainly due to the death and disintegration of the large adult worms.

Flammability and hazardous characteristics

Combustible; combustion produces toxic fumes of nitrogen oxides.

Clinical Use

Schistosomiasis Other trematode infections (except F. hepatica) Tapeworm infection, including cerebral cysticercosis Treatment may need to be prolonged in cerebral cysticercosis.

References

1.Andrews P, Thomas H, Pohlke R, Seubert J. Praziquantel (1983). Med Res Rev, 3, 147–200. 2. Xiao SH, Friedman PA, Catto BA, Webster LT Jr (1984). Praziquantel induced vesicle formation in the tegument of male mansoni is calcium dependent. J Parasitol, 70, 177–179. 3. Xiao SH, Catto BA, Webster LT Jr, Melborn H, Becker B (1984). Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis, 151, 1130–1137. 4. Pax R, Bennett JL, Fetterer R (1978). A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schmiedebergs Arch Pharmacol, 304, 309–315. 5. Davis A, Biles JE, Ulrich AM, Dixon H (1981). Tolerance and efficacy of praziquantel in phase IIA and IIB therapeutic trials in Zambian patients. Arzneimittelforschung, 31, 568–574. 6. Davis A, Biles JE, Ulrich AM (1979). Initial experiences in patients with Schistosoma mansoni previously treated with oxamniquine and/or hycanthone: Resistance of Schistosoma mansoni to schistosomicidal agents. Trans R Soc Trop Med Hyg, 76, 652–659. 7. Pugh RNH, Teesdale CH (1983). Single dose oral treatment in urinary schistosomiasis: a double blind trial. BMJ, 286, 429–432. 8. Ishizaki T, Kamo E, Boehme K (1979). Double-blind studies of tolerance to Praziquantel in Japanese patients with Schistosoma japonicum infections. Bull WHO, 57, 787–791. 9. Santos AT, Bias BL, Nosenas JS, Portillo GP, Ortega OM, Hayashi M, Boehme K (1979). Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines. Bull WHO, 57, 793–799. 10. Zhejiang Clinical Cooperative Research Group for praziquantel (1980). Clinical evaluation of praziquantel in treatment of schistosomiasis japonica. A report of 181 cases. Chin Med J, 93, 375–384. 11. Katz N, Rocha RS, Chaves A (1979). Preliminary trial with praziquantel in human infections due to Schistosoma mansoni. Bull WHO, 57, 781–785. 12. Watt G, Baldovino P, Castro J, Fernando M, Ranoa C (1986). Bloody diarrhea after praziquantel therapy. Trans R Soc Trop Med Hyg, 80, 345–346. 13. Polderman AM, Gryseels B, Gerold JL, Mpamila K, Manshande JP (1984). Side effects of praziquantel in the treatment of Schistosoma mansoni in Maniema, Zaire. Trans R Soc Trop Med Hyg, 78, 752–754. 14. Frohberg H, Schulze Schenking M (1981). Toxicological profile of praziquantel a new drug against cestode and Schistosoma infections as compared to some other schistosomicides. Arzneimittelforschung, 31, 555–565. 15. Pütter J, Held H (1979). Quantitative studies on the occurrence of praziquantel in milk and plasma of lactating women. Eur J Drug Metab Pharmacokinet, 4, 193–198. 16. Billings PC, Heidelberger C (1982). Effects of praziquantel a new antischistosomicide drug on the mutation and transformation of mamalian cells. Cancer Res, 42, 2692–2696. 17. Bittencourt PRM, Gracia CM, Martins R, Fernandes AG, Diekmann HW, Jung W (1992). Phenytoin and carbamazepine decrease oral bioavailability of praziquantel. Neurology, 42, 492–496. 18. Vazquez M, Jung H, Sotelo J (1987). Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology, 37, 1561–1562.

Side effects

Adverse reactions tend to occur within a few hours of administration. They include gastrointestinal intolerance with nausea, vomiting, and abdominal discomfort. This may be due to the liberation of helminth proteins from dead worms rather than any direct effect of the drug.

Side effects

In large-scale and community-based studies in patients and healthy volunteers, the drug showed only mild to moderate and transient side effects 【5—11】. The frequency and intensity of side effects seemed to be dose related. In one study【10】, the frequency of the side effects were: dizziness (29%), headache (15%), lassitude (19%), pain in the limbs (22%), and abdominal distress (9%). Nausea, insomnia, fever, and non-itching macular eruptions occurred in single patients. 40% of the patients remained free from any side effects. Abdominal colic and bloody diarrhoea due to praziquantel have been reported by others 【12, 13】. Praziquantel has not shown to be mutagenic or carcinogenic 【14, 15, 16】.
InChI:InChI=1/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2

55268-74-1 Well-known Company Product Price

Brand (Code)Product description CAS number Packaging Price Detail
TCI America (P2125)  Praziquantel  >98.0%(HPLC)(N) 55268-74-1 5g 490.00CNY Detail
TCI America (P2125)  Praziquantel  >98.0%(HPLC)(N) 55268-74-1 25g 1,690.00CNY Detail
Sigma-Aldrich (PHR1391)    pharmaceutical secondary standard; traceable to USP, PhEur 55268-74-1 PHR1391-1G 791.15CNY Detail
Sigma-Aldrich (P2670000)  Praziquantel  European Pharmacopoeia (EP) Reference Standard 55268-74-1 P2670000 1,880.19CNY Detail
Sigma-Aldrich (Y0001533)  Praziquantel for system suitability  European Pharmacopoeia (EP) Reference Standard 55268-74-1 Y0001533 1,880.19CNY Detail
USP (1554603)  Praziquantel  United States Pharmacopeia (USP) Reference Standard 55268-74-1 1554603-200MG 4,662.45CNY Detail
Sigma-Aldrich (46648)  Praziquantel  VETRANAL, analytical standard 55268-74-1 46648-250MG 525.33CNY Detail

55268-74-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name Praziquantel

1.2 Other means of identification

Product number -
Other names embay8440

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:55268-74-1 SDS

55268-74-1Synthetic route

4-(cyclohexanecarbonyl)-6-hydroxy-1-phenethylpiperazin-2-one
87693-75-2

4-(cyclohexanecarbonyl)-6-hydroxy-1-phenethylpiperazin-2-one

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With hydrogenchloride at 0℃;95%
With sulfuric acid3.0 g (95%)
With sulfuric acid In dichloromethane at 0 - 5℃; for 4h;170.1 g
4-(cyclohexanecarbonyl)-6-hydroxy-1-phenethylpiperazin-2-one
87693-75-2

4-(cyclohexanecarbonyl)-6-hydroxy-1-phenethylpiperazin-2-one

A

2-(cyclohexylcarbonyl)-1,3,4,6,7,11b-hexahydro-2H-pyrazino-(2,1-a)-4-isoquinoleinone (PRAZIQUANTEL)

2-(cyclohexylcarbonyl)-1,3,4,6,7,11b-hexahydro-2H-pyrazino-(2,1-a)-4-isoquinoleinone (PRAZIQUANTEL)

B

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
In 12N-hydrochloric acidA 95%
B n/a
2-(Cyclohexylcarbonyl)-2,3,6,7-tetrahydro-4H-pyrazino-<2,1-a>-isoquinolin-4-one

2-(Cyclohexylcarbonyl)-2,3,6,7-tetrahydro-4H-pyrazino-<2,1-a>-isoquinolin-4-one

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With palladium on activated charcoal; hydrogen In methanol at 20℃; under 760.051 Torr; for 19h; Solvent; Inert atmosphere;93%
cyclohexanylcarbonyl chloride
2719-27-9

cyclohexanylcarbonyl chloride

2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one
61196-37-0

2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With triethylamine In 1,2-dimethoxyethane for 15h; Ambient temperature;90%
With sodium carbonate In dichloromethane for 2h; Ambient temperature;85%
With triethylamine In 1,2-dimethoxyethane for 20h; Ambient temperature;70%
1-[2-(2-bromophenyl)ethyl]-4-(cyclohexylcarbonyl)-1,3,4-trihydropyrazin-2-one
406954-89-0

1-[2-(2-bromophenyl)ethyl]-4-(cyclohexylcarbonyl)-1,3,4-trihydropyrazin-2-one

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With 2,2'-azobis(isobutyronitrile); tri-n-butyl-tin hydride In toluene for 16h; Heating;90%
Multi-step reaction with 2 steps
1: caesium carbonate; tetrakis(triphenylphosphine) palladium(0) / N,N-dimethyl-formamide / 18 h / 80 °C / Inert atmosphere
2: palladium on activated charcoal; hydrogen / methanol / 19 h / 20 °C / 760.05 Torr / Inert atmosphere
View Scheme
Multi-step reaction with 2 steps
1: caesium carbonate; tetrakis(triphenylphosphine) palladium(0) / 2-methyltetrahydrofuran / 22 h / 80 °C / Inert atmosphere
2: palladium on activated charcoal; hydrogen / methanol / 19 h / 20 °C / 760.05 Torr / Inert atmosphere
View Scheme
N-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)cyclohexanecarboxylic acid amide
79848-93-4

N-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)cyclohexanecarboxylic acid amide

chloroacetyl chloride
79-04-9

chloroacetyl chloride

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With sodium hydroxide; N-benzyl-N,N,N-triethylammonium chloride In dichloromethane at 20 - 25℃; for 0.7h;88%
Stage #1: N-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)cyclohexanecarboxylic acid amide; chloroacetyl chloride With sodium hydroxide In dichloromethane for 0.5h;
Stage #2: With N-benzyl-N,N,N-triethylammonium chloride In dichloromethane for 2h; Reflux;
81%
Stage #1: N-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)cyclohexanecarboxylic acid amide; chloroacetyl chloride With sodium hydroxide In dichloromethane at 20℃; for 0.5h;
Stage #2: With benzyltrimethylammonium chloride In dichloromethane for 2h; Reflux;
78%
Stage #1: N-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)cyclohexanecarboxylic acid amide; chloroacetyl chloride With sodium hydroxide In dichloromethane at 0℃; for 0.5h;
Stage #2: With tetrabutylammomium bromide In dichloromethane for 3h; Reflux;
68%
With N-benzyl-N,N,N-triethylammonium chloride; sodium hydroxide In water Inert atmosphere;56%
C14H22N2O3*0.5H2O4S

C14H22N2O3*0.5H2O4S

cyclohexanylcarbonyl chloride
2719-27-9

cyclohexanylcarbonyl chloride

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Stage #1: C14H22N2O3*0.5H2O4S at 35 - 45℃; for 10h;
Stage #2: cyclohexanylcarbonyl chloride With lithium hydroxide In water at 5℃; for 5h;
86.5%
1-Cyclohexylcarbonylaminomethyl-2-chloracetyl-1,2,3,4-tetrahydro-isochinolin
60567-53-5, 60567-54-6, 104916-35-0

1-Cyclohexylcarbonylaminomethyl-2-chloracetyl-1,2,3,4-tetrahydro-isochinolin

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With sodium hydroxide; N-benzyl-N,N,N-triethylammonium chloride In benzene at 80℃; for 0.7h;86%
C14H22N2O3*H3O4P

C14H22N2O3*H3O4P

cyclohexanylcarbonyl chloride
2719-27-9

cyclohexanylcarbonyl chloride

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Stage #1: C14H22N2O3*H3O4P With phosphoric acid at 10 - 20℃; for 12h;
Stage #2: cyclohexanylcarbonyl chloride With calcium bicarbonate In water at 0℃; for 5h;
86%
cyclohexanylcarbonyl chloride
2719-27-9

cyclohexanylcarbonyl chloride

N-2-phenylethyl 2-N-(2,2-dimethoxyethylamino)acetamide hydrochloride
90142-14-6

N-2-phenylethyl 2-N-(2,2-dimethoxyethylamino)acetamide hydrochloride

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Stage #1: N-2-phenylethyl 2-N-(2,2-dimethoxyethylamino)acetamide hydrochloride With sulfuric acid In dichloromethane at 5 - 20℃; for 3.5h; Cooling with ice; Industrial scale;
Stage #2: cyclohexanylcarbonyl chloride With sodium carbonate at 5 - 20℃; for 2.5h; Reagent/catalyst; Solvent; Temperature; Industrial scale;
85.1%
N-(2,2-dimethoxyethyl)-N-(2-oxo-2-(2-phenethylamino)-ethyl)cyclohexanecarboxamide
90142-13-5

N-(2,2-dimethoxyethyl)-N-(2-oxo-2-(2-phenethylamino)-ethyl)cyclohexanecarboxamide

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With methanesulfonic acid In 1,2-dichloro-ethane for 6h; Heating;85%
Stage #1: N-(2,2-dimethoxyethyl)-N-(2-oxo-2-(2-phenethylamino)-ethyl)cyclohexanecarboxamide With methanesulfonic acid at 0 - 70℃; for 6h; Pictet-Spengler cyclisation;
Stage #2: With water; sodium hydroxide pH=8; Pictet-Spengler cyclisation; Cooling with ice;
65%
Multi-step reaction with 2 steps
1: 95 percent / methanesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
2: conc. H2SO4 / 3 h / Ambient temperature
View Scheme
C14H22N2O3*H2O4S

C14H22N2O3*H2O4S

cyclohexanylcarbonyl chloride
2719-27-9

cyclohexanylcarbonyl chloride

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Stage #1: C14H22N2O3*H2O4S With sulfuric acid at 0 - 5℃; for 10h;
Stage #2: cyclohexanylcarbonyl chloride With sodium carbonate In water at 0℃; for 4.5h;
85%
C19H26N2O3

C19H26N2O3

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 10h; Reagent/catalyst; Solvent; Temperature; Cooling with ice;76.8%
N-(2,2-diethoxy)ethyl-N-2-phenylethyl 2-N-cyclohexylcarbonylaminoacetamide
97004-08-5

N-(2,2-diethoxy)ethyl-N-2-phenylethyl 2-N-cyclohexylcarbonylaminoacetamide

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With methanesulfonic acid In dichloromethane for 48h; Heating;73%
Multi-step reaction with 2 steps
1: 91 percent / methanesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
2: conc. H2SO4 / 3 h / Ambient temperature
View Scheme
C14H22N2O3*(x)ClH

C14H22N2O3*(x)ClH

cyclohexanylcarbonyl chloride
2719-27-9

cyclohexanylcarbonyl chloride

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Stage #1: C14H22N2O3*(x)ClH at 10 - 15℃; for 8h;
Stage #2: cyclohexanylcarbonyl chloride With calcium hydroxide In water at 10℃; for 4h;
70.9%
4-(cyclohexylcarbonyl)-3,4-dihydro-1-(2-phenylethyl)-2(1H)-pyrazinone
94494-35-6

4-(cyclohexylcarbonyl)-3,4-dihydro-1-(2-phenylethyl)-2(1H)-pyrazinone

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With sulfuric acid at 20℃; for 3h;70%
With sulfuric acid for 3h; Ambient temperature; Yield given;
cyclohexanecarboxylic acid {[(2-ethoxy-2-(polystyryl)oxy-ethyl)-phenethyl-carbamoyl]-methyl}-amide, via coupling with (cyclohexanecarbonyl-amino)-acetic acid

cyclohexanecarboxylic acid {[(2-ethoxy-2-(polystyryl)oxy-ethyl)-phenethyl-carbamoyl]-methyl}-amide, via coupling with (cyclohexanecarbonyl-amino)-acetic acid

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With methanesulfonic acid In nitromethane at 60℃; for 16h;57%
Cyclohexanecarboxylic acid bicyclo[4.2.0]octa-1,3,5-trien-7-ylmethyl-[(methoxymethyl-carbamoyl)-methyl]-amide
93255-08-4

Cyclohexanecarboxylic acid bicyclo[4.2.0]octa-1,3,5-trien-7-ylmethyl-[(methoxymethyl-carbamoyl)-methyl]-amide

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
at 400 - 425℃; for 8h;49%
N-(2-phenylethyl)-N-(cyanomethyl)amide of cyclohexylcarbonylglycine
152189-66-7

N-(2-phenylethyl)-N-(cyanomethyl)amide of cyclohexylcarbonylglycine

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With formic acid; sulfuric acid; nickel 1.) water, reflux, 1 h, 2.) 20 deg C, 3 h; Yield given. Multistep reaction;
Multi-step reaction with 2 steps
1: 53 percent / formic acid, Raney Ni / H2O / 1 h / Heating
2: 70 percent / conc. H2SO4 / 3 h / 20 °C
View Scheme
(cyclohexanecarbonyl-amino)-acetic acid
32377-88-1

(cyclohexanecarbonyl-amino)-acetic acid

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 88 percent / PyBroP; 1-hydroxy-7-azabenzotriazole; DIPEA / CH2Cl2 / 48 h / 20 °C
2: 76 percent / tin(II) trifluoromethanesulfonate / acetone / 48 h / 40 °C
3: 90 percent / AIBN; Bu3SnH / toluene / 16 h / Heating
View Scheme
Multi-step reaction with 3 steps
1: 1.) dicyclohexylcarbodiimide / 1.) CHCl3, 20 deg C, 30 min, 2.) CHCl3, 20 deg C, 76 h
2: 53 percent / formic acid, Raney Ni / H2O / 1 h / Heating
3: 70 percent / conc. H2SO4 / 3 h / 20 °C
View Scheme
Multi-step reaction with 2 steps
1: 1.) dicyclohexylcarbodiimide / 1.) CHCl3, 20 deg C, 30 min, 2.) CHCl3, 20 deg C, 76 h
2: 1.) Raney Ni, formic acid, 2.) conc. H2SO4 / 1.) water, reflux, 1 h, 2.) 20 deg C, 3 h
View Scheme
2-(2-bromophenyl)ethanamine
65185-58-2

2-(2-bromophenyl)ethanamine

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 40 percent / NaBH(OAc)3 / 1,2-dichloro-ethane; various solvent(s) / 3 h / 20 °C
2: 88 percent / PyBroP; 1-hydroxy-7-azabenzotriazole; DIPEA / CH2Cl2 / 48 h / 20 °C
3: 76 percent / tin(II) trifluoromethanesulfonate / acetone / 48 h / 40 °C
4: 90 percent / AIBN; Bu3SnH / toluene / 16 h / Heating
View Scheme
Multi-step reaction with 3 steps
1: 68 percent / 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; HOBt; DMAP / CH2Cl2 / 16 h / 20 °C
2: 60 percent / tin(II) trifluoromethanesulfonate / acetone / 40 °C
3: 90 percent / AIBN; Bu3SnH / toluene / 16 h / Heating
View Scheme
phenylmethyl 2-(cyclohexylcarbonylamino)acetate
243139-85-7

phenylmethyl 2-(cyclohexylcarbonylamino)acetate

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 98 percent / H2 / Pd/C / aq. ethanol / 1.5 h
2: 88 percent / PyBroP; 1-hydroxy-7-azabenzotriazole; DIPEA / CH2Cl2 / 48 h / 20 °C
3: 76 percent / tin(II) trifluoromethanesulfonate / acetone / 48 h / 40 °C
4: 90 percent / AIBN; Bu3SnH / toluene / 16 h / Heating
View Scheme
(2,2-dimethoxyethyl)-[2-(2-bromophenyl)ethyl]amine
406954-90-3

(2,2-dimethoxyethyl)-[2-(2-bromophenyl)ethyl]amine

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 88 percent / PyBroP; 1-hydroxy-7-azabenzotriazole; DIPEA / CH2Cl2 / 48 h / 20 °C
2: 76 percent / tin(II) trifluoromethanesulfonate / acetone / 48 h / 40 °C
3: 90 percent / AIBN; Bu3SnH / toluene / 16 h / Heating
View Scheme
2-[N-(2,2-dimethoxyethyl)cyclohexylcarbonylamino]acetic acid
60744-45-8

2-[N-(2,2-dimethoxyethyl)cyclohexylcarbonylamino]acetic acid

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 68 percent / 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; HOBt; DMAP / CH2Cl2 / 16 h / 20 °C
2: 60 percent / tin(II) trifluoromethanesulfonate / acetone / 40 °C
3: 90 percent / AIBN; Bu3SnH / toluene / 16 h / Heating
View Scheme
phenylmethyl 2-[N-(2,2-dimethoxyethyl)cyclohexylcarbonylamino]acetate
406954-87-8

phenylmethyl 2-[N-(2,2-dimethoxyethyl)cyclohexylcarbonylamino]acetate

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 98 percent / H2 / Pd/C / aq. ethanol
2: 68 percent / 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; HOBt; DMAP / CH2Cl2 / 16 h / 20 °C
3: 60 percent / tin(II) trifluoromethanesulfonate / acetone / 40 °C
4: 90 percent / AIBN; Bu3SnH / toluene / 16 h / Heating
View Scheme
N-(2,2-dimethoxyethyl)-N-(2-oxo-2-(2-(2-bromophenyl)ethylamino)ethyl)cyclohexanecarboxamide
406954-88-9

N-(2,2-dimethoxyethyl)-N-(2-oxo-2-(2-(2-bromophenyl)ethylamino)ethyl)cyclohexanecarboxamide

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 60 percent / tin(II) trifluoromethanesulfonate / acetone / 40 °C
2: 90 percent / AIBN; Bu3SnH / toluene / 16 h / Heating
View Scheme
N-(2,2-dimethoxyethyl)-N-[2-(2-bromophenyl)ethyl]-2-(cyclohexylcarbonylamino)acetamide
406954-91-4

N-(2,2-dimethoxyethyl)-N-[2-(2-bromophenyl)ethyl]-2-(cyclohexylcarbonylamino)acetamide

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 76 percent / tin(II) trifluoromethanesulfonate / acetone / 48 h / 40 °C
2: 90 percent / AIBN; Bu3SnH / toluene / 16 h / Heating
View Scheme
Cyclohexanecarboxylic acid
98-89-5

Cyclohexanecarboxylic acid

Nα-Fmoc-Nim-tert-butyloxycarbonyl-L-tryptophan 4-hydroxymethylphenoxy resin

Nα-Fmoc-Nim-tert-butyloxycarbonyl-L-tryptophan 4-hydroxymethylphenoxy resin

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 61 percent / 1-hydroxybenzotriazole hydrate; 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; 4-dimethylaminopyridine / CH2Cl2 / 16 h / 20 °C
2: 98 percent / H2 / Pd/C / aq. ethanol / 1.5 h
3: 88 percent / PyBroP; 1-hydroxy-7-azabenzotriazole; DIPEA / CH2Cl2 / 48 h / 20 °C
4: 76 percent / tin(II) trifluoromethanesulfonate / acetone / 48 h / 40 °C
5: 90 percent / AIBN; Bu3SnH / toluene / 16 h / Heating
View Scheme
Multi-step reaction with 5 steps
1: 61 percent / 1-hydroxybenzotriazole hydrate; 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; 4-dimethylaminopyridine / CH2Cl2 / 16 h / 20 °C
2: 98 percent / H2 / Pd/C / aq. ethanol / 1.5 h
3: 88 percent / PyBroP; 1-hydroxy-7-azabenzotriazole; DIPEA / CH2Cl2 / 48 h / 20 °C
4: 76 percent / tin(II) trifluoromethanesulfonate / acetone / 48 h / 40 °C
5: 90 percent / AIBN; Bu3SnH / toluene / 16 h / Heating
View Scheme
Multi-step reaction with 5 steps
1: 82 percent / PyBroP; 1-hydroxy-7-azabenzotriazole; DIPEA / CH2Cl2 / 16 h / 20 °C
2: 98 percent / H2 / Pd/C / aq. ethanol
3: 68 percent / 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; HOBt; DMAP / CH2Cl2 / 16 h / 20 °C
4: 60 percent / tin(II) trifluoromethanesulfonate / acetone / 40 °C
5: 90 percent / AIBN; Bu3SnH / toluene / 16 h / Heating
View Scheme
N-(2-phenylethyl)aminoacetaldehyde diethyl acetal
94508-09-5

N-(2-phenylethyl)aminoacetaldehyde diethyl acetal

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 1.) NEt3 / 1.) CH2Cl2, 0 deg C, 1 h; 2.) CH2Cl2, reflux, 7 h
2: 91 percent / methanesulfonic acid / CH2Cl2 / 3 h / Ambient temperature
3: conc. H2SO4 / 3 h / Ambient temperature
View Scheme
N,N-dimethyl-formamide
68-12-2, 33513-42-7

N,N-dimethyl-formamide

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

4-chloro-2-(cyclohexylcarbonyl)-2,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-3-yldimethyliminiomethane perchlorate

4-chloro-2-(cyclohexylcarbonyl)-2,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-3-yldimethyliminiomethane perchlorate

Conditions
ConditionsYield
Stage #1: N,N-dimethyl-formamide With trichlorophosphate at 20℃; for 1h;
Stage #2: 2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one at 60℃; for 5h; Vilsmeier formylation;
Stage #3: With perchloric acid In methanol
95%
2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one
61196-37-0

2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one

Conditions
ConditionsYield
With hydrogenchloride In water Reflux;91.2%
With hydrogenchloride In ethanol for 60h; Reflux;83%
Stage #1: 2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one With hydrogenchloride; water for 24h; Reflux;
Stage #2: With sodium hydroxide In water regioselective reaction;
80%
2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

2-<2-N-(cyclohexylcarbonyl)-N-formyl-amioacyl>-1,2,3,4-tetrahydroisoquinolin-1-one

2-<2-N-(cyclohexylcarbonyl)-N-formyl-amioacyl>-1,2,3,4-tetrahydroisoquinolin-1-one

Conditions
ConditionsYield
With 3-chloro-benzenecarboperoxoic acid In dichloromethane for 168h; Ambient temperature;81%
Multi-step reaction with 2 steps
1: 38 percent / sulfur / 2 h / 180 °C
2: 73 percent / 85percent MCPBA / CH2Cl2
View Scheme
4-methoxy-benzaldehyde
123-11-5

4-methoxy-benzaldehyde

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

2-(cyclohexylcarbonyl)-3-(4-methoxybenzylidene)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one
1403763-77-8

2-(cyclohexylcarbonyl)-3-(4-methoxybenzylidene)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With sodium hydroxide In ethanol for 3h; Claisen-Schmidt Condensation; Reflux;75%
2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

2-cyclohexylthiocarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinoline-4-thione

2-cyclohexylthiocarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinoline-4-thione

Conditions
ConditionsYield
With Lawessons reagent In toluene for 3h; Heating;70%
thiophene-2-carbaldehyde
98-03-3

thiophene-2-carbaldehyde

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

2-(cyclohexylcarbonyl)-3-(thiophen-2-methylene)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one
1403763-78-9

2-(cyclohexylcarbonyl)-3-(thiophen-2-methylene)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With sodium hydroxide In ethanol for 3h; Claisen-Schmidt Condensation; Reflux;70%
4-methylpiperidin
626-58-4

4-methylpiperidin

formaldehyd
50-00-0

formaldehyd

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

2-(cyclohexylcarbonyl)-3-((4-methylpiperidin-1-yl)methyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one
1403763-80-3

2-(cyclohexylcarbonyl)-3-((4-methylpiperidin-1-yl)methyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Stage #1: 4-methylpiperidin; formaldehyd In ethanol for 0.5h; Mannich Aminomethylation; Reflux;
Stage #2: 2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one In ethanol for 8h; Reflux;
65%
1-methyl-piperazine
109-01-3

1-methyl-piperazine

formaldehyd
50-00-0

formaldehyd

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

2-2-(cyclohexylcarbonyl)-3-((4-methylpiperazin-1-yl)methyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one
1403763-79-0

2-2-(cyclohexylcarbonyl)-3-((4-methylpiperazin-1-yl)methyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Stage #1: 1-methyl-piperazine; formaldehyd In ethanol for 0.5h; Mannich Aminomethylation; Reflux;
Stage #2: 2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one In ethanol for 8h; Reflux;
60%
formaldehyd
50-00-0

formaldehyd

di-n-propylamine
142-84-7

di-n-propylamine

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

2-(cyclohexylcarbonyl)-3-dipropylaminomethyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one
1403763-81-4

2-(cyclohexylcarbonyl)-3-dipropylaminomethyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Stage #1: formaldehyd; di-n-propylamine In ethanol for 0.5h; Mannich Aminomethylation; Reflux;
Stage #2: 2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one In ethanol for 8h; Reflux;
60%
formaldehyd
50-00-0

formaldehyd

ethanolamine
141-43-5

ethanolamine

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

2-2-(cyclohexylcarbonyl)-3-((2-hydroxyethylamino)methyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one
1403763-82-5

2-2-(cyclohexylcarbonyl)-3-((2-hydroxyethylamino)methyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
Stage #1: formaldehyd; ethanolamine In ethanol for 0.5h; Mannich Aminomethylation; Reflux;
Stage #2: 2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one In ethanol for 8h; Reflux;
60%
benzaldehyde
100-52-7

benzaldehyde

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

2-(cyclohexylcarbonyl)-3-benzylidene-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one
1403763-76-7

2-(cyclohexylcarbonyl)-3-benzylidene-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With sodium hydroxide In ethanol for 3h; Claisen-Schmidt Condensation; Reflux;60%
2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
55268-74-1

2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one

2-cyclohexylthiocarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2-1a]isoquinolin-4-one

2-cyclohexylthiocarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2-1a]isoquinolin-4-one

Conditions
ConditionsYield
With Lawessons reagent In toluene for 3h; Heating;50%
Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 55268-74-1